Diabetic dyslipidemia and exercise alter the plasma low-density lipoproteome in Yucatan pigs

Proteomics

Volumn 9, Issue 9, 2009, Pages 2468-2483

  Richardson, Matthew R ^a   Lai, Xianyin ^a   Dixon, Joseph L ^b   Sturek, Michael ^a   Witzmann, Frank A ^a  

^a INDIANA UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b RUTGERS UNIVERSITY   (United States)

Author keywords

Fast protein liquid chromatography; Low density lipoprotein; Tandem mass spectrometry; Two dimensional gel electrophoresis; Yucatan pig

Indexed keywords

ADIPONECTIN; APOLIPOPROTEIN A1; APOLIPOPROTEIN B; APOLIPOPROTEIN C3; APOLIPOPROTEIN D; APOLIPOPROTEIN E; CHOLESTEROL; CLUSTERIN; COMPLEMENT COMPONENT C1Q; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; LOW DENSITY LIPOPROTEIN; LOW DENSITY LIPOPROTEIN CHOLESTEROL;

AMINO ACID SEQUENCE; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; ATHEROSCLEROSIS; CARDIOVASCULAR RISK; CHOLESTEROL BLOOD LEVEL; CONTROLLED STUDY; DIABETES MELLITUS; DYSLIPIDEMIA; EXERCISE; HYPERLIPIDEMIA; LIPOPROTEIN BLOOD LEVEL; LIQUID CHROMATOGRAPHY; MALE; MASS SPECTROMETRY; NONHUMAN; PATHOPHYSIOLOGY; PRIORITY JOURNAL; PROTEIN ANALYSIS; PROTEIN BLOOD LEVEL; PROTEIN EXPRESSION; PROTEIN ISOLATION; SWINE; TWO DIMENSIONAL ELECTROPHORESIS; WESTERN BLOTTING;

ANALYSIS OF VARIANCE; ANIMALS; CHROMATOGRAPHY, LIQUID; DIABETES COMPLICATIONS; DIET, ATHEROGENIC; DISEASE MODELS, ANIMAL; DYSLIPIDEMIAS; ELECTROPHORESIS, GEL, TWO-DIMENSIONAL; GENE EXPRESSION REGULATION; LINEAR MODELS; LIPOPROTEINS, LDL; MALE; MODELS, MOLECULAR; PHYSICAL CONDITIONING, ANIMAL; SWINE; TANDEM MASS SPECTROMETRY;

ANIMALIA; SUIDAE;

EID: 66249143763     PISSN: 16159853     EISSN: 16159861     Source Type: Journal    
DOI: 10.1002/pmic.200800613     Document Type: Article

References (50)

1. Karlsson, H., Leanderson, P., Tagesson, C., Lindahl, M., Lipo- proteomics I: mapping of proteins in low-density lipoprotein using two-dimensional gel electrophoresis and mass spectrometry. Proteomics 2005, 5, 551-565.
2. Stahlman, M., Davidsson, P., Kanmert, I., Rosengren, B. etal., Proteomics and lipids of lipoproteins isolated at low salt concentrations in D2O/sucrose or in KBr. J. Lipid Res. 2008, 49, 481-490.
3. Ordovas, J. M., Osgood, D., Preparative isolation of plasma lipoproteins using fast protein liquid chromatography (FPLC). Methods Mol. Biol. 1998, 770, 105-111.
4. Stocker, R., Keaney, J. F., Jr., Role of oxidative modifications in atherosclerosis. Physiol. Rev. 2004, 84, 1381-1478.
5. Hennekens, C. H., Buring, J. E., Manson, J. E., Stampfer, M. et al., Lack of effect of long-term supplementation with beta carotene on the incidence of malignant neoplasms and cardiovascular disease. N.Engl. J. Med. 1996, 334, 1145-1149.
6. Omenn, G. S., Goodman, G. E., Thornquist, M. D., Balmes, J. etal., Effects of a combination of beta carotene and vitamin A on lung cancer and cardiovascular disease. N. Engl. J. Med. 1996, 334, 1150-1155.
7. Yusuf, S., Dagenais, G., Pogue, J., Bosch, J., Sleight, P., Vitamin E supplementation and cardiovascular events in high-risk patients. The Heart Outcomes Prevention Evaluation Study Investigators. N. Engl. J. Med. 2000, 342, 154-160.
8. Bucala, R., What is the effect of hyperglycemia on ather- ogenesis and can it be reversed by aminoguanidine? Diabetes Res. Clin. Pract. 1996, 30 Suppl, 123-130.
9. Blair, S. N., Kampert, J. B., Kohl, H. W., 3rd, Barlow, C. E. et al., Influences of cardiorespiratory fitness and other precursors on cardiovascular disease and all-cause mortality in men and women. JAMA 1996, 276, 205-210.
10. Cohn, J. S., Rodriguez, C., Jacques, H., Tremblay, M., Davignon, J., Storage of human plasma samples leads to alterations in the lipoprotein distribution of apoC-III and apoE. J. Lipid Res. 2004, 45, 1572-1579.
11. Dixon, J. L., Shen, S., Vuchetich, J. P., Wysocka, E. et al., Increased atherosclerosis in diabetic dyslipidemic swine: protection by atorvastatin involves decreased VLDL trigly- cerides but minimal effects on the lipoprotein profile. J. Lipid Res. 2002, 43, 1618-1629.
12. Weng, S., Zemany, L., Standley, K. N., Novack, D. V. et al., Beta3 integrin deficiency promotes atherosclerosis and pulmonary inflammation in high-fat-fed, hyperlipidemic mice. Proc. Natl. Acad. Sci. USA 2003, 700, 6730-6735.
13. Mokelke, E. A., Hu, Q., Song, M., Toro, L. etal., Altered functional coupling of coronary K+ channels in diabetic dyslipi- demic pigs is prevented by exercise. J. Appl. Physiol. 2003, 95, 1179-1193.
14. Witzmann, F. A., Richardson, M. R., Two-dimensional gels for toxicological drug discovery applications. Expert. Opin. Drug Metab. Toxicol. 2006, 2, 103-111.
15. Steiner, G., The dyslipoproteinemias of diabetes. Atherosclerosis 1994, 7 70 Suppl, S27-33.
16. Wamhoff, B. R., Dixon, J. L., Sturek, M., Atorvastatin treatment prevents alterations in coronary smooth muscle nuclear Ca2+ signaling in diabetic dyslipidemia. J. Vasc. Res. 2002, 39, 208-220.
17. Boullion, R. D., Mokelke, E. A., Wamhoff, B. R., Otis, C. R. et al., Porcine model of diabetic dyslipidemia: insulin and feed algorithms for mimicking diabetes mellitus in humans. Comp. Med. 2003, 53, 42-52.
18. Dixon, J. L., Stoops, J. D., Parker, J. L., Laughlin, M. H. etal., Dyslipidemia and vascular dysfunction in diabetic pigs fed an atherogenic diet. Arterioscler. Thromb. Vasc. Biol. 1999, 79, 2981-2992.
19. Neuhoff, V., Arold, N., Taube, D., Ehrhardt, W., Improved staining of proteins in polyacrylamide gels including iso- electric focusing gels with clear background at nanogram sensitivity using Coomassie Brilliant Blue G-250 and R-250. Electrophoresis 1988, 9, 255-262.
20. Bolstad, B. M., Irizarry, R. A., Astrand, M., Speed, T. P., A comparison of normalization methods for high density oli- gonucleotide array data based on variance and bias. Bioin- formatics 2003, 79, 185-193.
21. Laemmli, U. K., Cleavage of structural proteins during the assembly of the head of bacteriophage T4. Nature 1970, 227, 680-685.
22. Reed, E., Platinum-DNA adduct, nucleotide excision repair and platinum based anti-cancer chemotherapy. Cancer Treat. Rev. 1998, 24, 331-344.
23. Higgs, R. E., Knierman, M. D., Gelfanova, V., Butler, J. P., Hale, J. E., Comprehensive label-free method for the relative quantification of proteins from biological samples. J. Pro- teome Res. 2005, 4, 1442-1450.
24. Hale, J. E., Butler, J. P., Gelfanova, V., You, J. S., Knierman, M. D., A simplified procedure for the reduction and alkyla- tion of cysteine residues in proteins prior to proteolytic digestion and mass spectral analysis. Anal. Biochem. 2004, 333, 174-181.
25. Mahley, R. W., Apolipoprotein E: cholesterol transport protein with expanding role in cell biology. Science 1988, 240, 622-630.
26. Carr, S., Aebersold, R., Baldwin, M., Burlingame, A. et al., The need for guidelines in publication of peptide and protein identification data: Working Group on Publication Guidelines for Peptide and Protein Identification Data. Mol. Cell. Proteomics 2004, 3, 531-533.
27. Geiss, H. C., Parhofer, K. G., Donner, M. G., Schwandt, P., Low density lipoprotein apheresis by membrane differential filtration (cascade filtration). Ther. Apher. 1999, 3, 199-202.
28. Hollander, W., Colombo, M. A., Kirkpatrick, B., Paddock, J., Soluble proteins in the human atherosclerotic plaque. With spectral reference to immunoglobulins, C3-complement component, alpha 1-antitrypsin and alpha 2-macroglobulin. Atherosclerosis 1979, 34, 391-405.
29. Karbowska, J., Kochan, Z., Role of adiponectin in the regulation of carbohydrate and lipid metabolism. J. Physiol. Pharmacol. 2006, 57Suppl 6, 103-113.
30. Matsuzawa, Y., Adiponectin: Identification, physiology and clinical relevance in metabolic and vascular disease. Atherosclerosis Suppl. 2005, 6, 7-14.
31. Marso, S. P., Mehta, S. K., Frutkin, A., House, J. A. etal., Low adiponectin levels are associated with atherogenic dyslipi- demia and lipid-rich plaque in nondiabetic coronary arteries. Diabetes Care 2008, 37, 989-994.
32. Kobayashi, K., Inoguchi, T., Sonoda, N., Sekiguchi, N., Nawata, H., Adiponectin inhibits the binding of low-density lipoprotein to biglycan, a vascular proteoglycan. Biochem. Biophys. Res. Commun. 2005, 335, 66-70.
33. Kannel, W. B., Overview of hemostatic factors involved in atherosclerotic cardiovascular disease. Lipids 2005, 40, 1215-1220.
34. Klein, R. L., Hunter, S. J., Jenkins, A. J., Zheng, D. et al., Fi- brinogen is a marker for nephropathy and peripheral vascular disease in type 1 diabetes: studies of plasma fibrino- gen and fibrinogen gene polymorphism in the DCCT/EDIC cohort. Diabetes Care 2003, 26, 1439-1448.
35. Shukla, S. D., Kansra, S. V., Reddy, M. A., Shukla, S. M. etal., Diabetic pig platelets exhibit hypersensitivity to thrombin. Comp. Med. 2008, 58, 481-484.
36. Festa, A., Kopp, H. P., Schernthaner, G., Menzel, E. J., Auto- antibodies to oxidised low density lipoproteins in IDDM are inversely related to metabolic control and microvascular complications. Diabetologia 1998, 47, 350-356.
37. Kostner, K. M., Activation of the complement system: a crucial link between inflammation and atherosclerosis? Eur. J. Clin. Invest. 2004, 34, 800-802.
38. Ceriello, A., Giugliano, D., Quatraro, A., Stante, A. et al., Increased alpha 2-macroglobulin in diabetes: a hyperglyce- mia related phenomenon associated with reduced antith- rombin III activity. Acta Diabetol. Lat. 1989, 26, 147-154.
39. James, K., Merriman, J., Gray, R. S., Duncan, L. J., Herd, R., Serum alpha 2-macroglobulin levels in diabetes. J. Clin. Pathol. 1980, 33, 163-166.
40. Inoue, W., Immunopathological analysis of acute phase reactant (APR) proteins in glomeruli from patients with diabetic nephropathy. Nippon Jinzo Gakkai Shi 1989, 31, 211-219.
41. Otto, C., Ritter, M. M., Richter, W. O., Minkenberg, R., Schwandt, P., Hemorrheologic abnormalities in defined primary dyslipoproteinemias with both high and low atherosclerotic risks. Metabolism 2001, 50, 166-170.
42. Mori, T., Sasaki, J., Kawaguchi, H., Handa, K. et al., Serum glycoproteins and severity of coronary atherosclerosis. Am. Heart J. 1995, 129, 234-238.
43. Wang, Y., Xu, L. Y., Lam, K. S., Lu, G. etal., Proteomic characterization of human serum proteins associated with the fat-derived hormone adiponectin. Proteomics 2006, 6, 38623870.
44. Savkovic, V., Gantzer, H., Reiser, U., Selig, L. et al., Clusterin is protective in pancreatitis through anti-apoptotic and antiinflammatory properties. Biochem. Biophys. Res. Commun. 2007, 356, 431-437.
45. Woods, J. A., Vieira, V. J., Keylock, K. T., Exercise, inflammation, and innate immunity. Neurol. Clin. 2006, 24, 585599.
46. Gelissen, I. C., Hochgrebe, T., Wilson, M. R., Easterbrook- Smith, S. B. et al., Apolipoprotein J (clusterin) induces cholesterol export from macrophage-foam cells: a potential anti-atherogenic function? Biochem. J. 1998, 331(Pt 1), 231-237.
47. Faro, J., Chen, Y., Jhaveri, P., Oza, P. et al., L-ficolin binding and lectin pathway activation by acetylated low-density lipoprotein. Clin. Exp. Immunol. 2008, 151, 275-283.
48. Harazono, A., Kawasaki, N., Kawanishi, T., Hayakawa, T., Site-specific glycosylation analysis of human apolipopro- tein B100 using LC/ESI MS/MS. Glycobiology 2005, 15, 447462.
49. Paananen, K., Saarinen, J., Annila, A., Kovanen, P. T., Pro- teolysis and fusion of low density lipoprotein particles strengthen their binding to human aortic proteoglycans. J. Biol. Chem. 1995, 270, 12257-12262.
50. Eugster, C., Panakova, D., Mahmoud, A., Eaton, S., Lipopro- tein-heparan sulfate interactions in the Hh pathway. Dev. Cell2007, 13, 57-71.